# Eli Lilly to acquire Adverum Biotechnologies

Eli Lilly and Company has announced a definitive agreement to acquire Adverum Biotechnologies, including its lead product candidate Ixo-vec, a Phase 3 gene therapy for wet age-related macular degeneration.

- Type: Acquisition
- Announced: 2025-10-24
- Where: United States
- Status: announced
- Products: Ixo-vec gene therapy for wet age-related macular degeneration
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Eli Lilly and Company](https://endata.com/companies/16522.md) (acquirer)
- [Adverum Biotechnologies](https://endata.com/companies/88042.md) (target)

## Sources

- [investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-adverum-biotechnologies), 2025-10-24: "Ixo-vec has the potential to transform wAMD treatment from a paradigm of chronic care with repeated intravitreal injections to a convenient one-time therapy"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.